Genentech’s gantenerumab granted FDA breakthrough designation in AD
Roche’s subsidiary Genentech has received the US Food and Drug Administration (FDA) breakthrough therapy designation for its anti-amyloid beta antibody therapy Gantenerumab to treat Alzheimer’s disease (AD). Gantenerumab